Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Relative Bioavailability Of Ibupirac 40 mg/ml (Laboratorios Pfizer LTDA) Oral Suspension Form Versus Alivium® 50mg/ml (Mantecorp Industria Quimicae Farmaceutica LTDA.) Oral Suspension Form, Under Fasted Conditions In Healthy Volunteers.

NCT01466517 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01466517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Relative Bioavailability Of Ibupirac 40 mg/ml (Laboratorios Pfizer LTDA) Oral Suspension Form Versus Alivium® 50mg/ml (Mantecorp Industria Quimicae Farmaceutica LTDA.) Oral Suspension Form, Under Fasted Conditions In Healthy Volunteers.
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2011
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy